Protective effects of lovastatin in a population-based ALS study and mouse model.

Lovastatin reduced risk of ALS in humans, which was confirmed in an ALS mouse model by delayed symptom onset, prolonged survival, and preservation of motor neurons. While further studies to understand the mechanism are required, lovastatin may represent a potential neuroprotective therapy for patients with ALS. These data demonstrate the utility of a combined pharmacoepidemiologic and mouse model approach. This article is protected by copyright. All rights reserved.